CellaVision AB (publ) (CEVI.ST)
SEK 222.0
(2.07%)
SEK 222.0
(2.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 212.32 Million SEK | -15.11% |
| 2022 | 250.12 Million SEK | -11.28% |
| 2021 | 281.93 Million SEK | 18.26% |
| 2020 | 238.4 Million SEK | -18.73% |
| 2019 | 293.33 Million SEK | 255.96% |
| 2018 | 82.4 Million SEK | 37.93% |
| 2017 | 59.74 Million SEK | 18.85% |
| 2016 | 50.27 Million SEK | 36.2% |
| 2015 | 36.91 Million SEK | -27.56% |
| 2014 | 50.95 Million SEK | -9.11% |
| 2013 | 56.05 Million SEK | 4.5% |
| 2012 | 53.64 Million SEK | 1.87% |
| 2011 | 52.66 Million SEK | 7.3% |
| 2010 | 49.07 Million SEK | 27.3% |
| 2009 | 38.55 Million SEK | -23.64% |
| 2008 | 50.48 Million SEK | 109.95% |
| 2007 | 24.04 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 217.98 Million SEK | 1.22% |
| 2024 Q3 | 215.97 Million SEK | -0.92% |
| 2024 Q1 | 215.35 Million SEK | 1.43% |
| 2023 Q4 | 212.32 Million SEK | -1.95% |
| 2023 Q1 | 232.78 Million SEK | -6.93% |
| 2023 Q2 | 238.52 Million SEK | 2.47% |
| 2023 FY | 212.32 Million SEK | -15.11% |
| 2023 Q3 | 216.54 Million SEK | -9.21% |
| 2022 Q2 | 256.88 Million SEK | -2.88% |
| 2022 Q4 | 250.12 Million SEK | -1.76% |
| 2022 FY | 250.12 Million SEK | -11.28% |
| 2022 Q1 | 264.5 Million SEK | -6.18% |
| 2022 Q3 | 254.59 Million SEK | -0.89% |
| 2021 Q4 | 281.93 Million SEK | 14.37% |
| 2021 Q1 | 244 Million SEK | 2.35% |
| 2021 FY | 281.93 Million SEK | 18.26% |
| 2021 Q2 | 254.36 Million SEK | 4.25% |
| 2021 Q3 | 246.49 Million SEK | -3.09% |
| 2020 Q2 | 266.15 Million SEK | -9.68% |
| 2020 Q1 | 294.69 Million SEK | 0.46% |
| 2020 FY | 238.4 Million SEK | -18.73% |
| 2020 Q4 | 238.4 Million SEK | -5.82% |
| 2020 Q3 | 253.15 Million SEK | -4.89% |
| 2019 Q1 | 103.34 Million SEK | 25.41% |
| 2019 Q2 | 107.86 Million SEK | 4.37% |
| 2019 Q4 | 293.33 Million SEK | 165.4% |
| 2019 Q3 | 110.52 Million SEK | 2.47% |
| 2019 FY | 293.33 Million SEK | 255.96% |
| 2018 Q1 | 58.33 Million SEK | -2.36% |
| 2018 Q4 | 82.4 Million SEK | 17.4% |
| 2018 FY | 82.4 Million SEK | 37.93% |
| 2018 Q3 | 70.19 Million SEK | 1.17% |
| 2018 Q2 | 69.38 Million SEK | 18.94% |
| 2017 FY | 59.74 Million SEK | 18.85% |
| 2017 Q4 | 59.74 Million SEK | 10.82% |
| 2017 Q2 | 47.25 Million SEK | 2.07% |
| 2017 Q1 | 46.29 Million SEK | -7.91% |
| 2017 Q3 | 53.91 Million SEK | 14.1% |
| 2016 Q1 | 39.5 Million SEK | 7.03% |
| 2016 Q3 | 46.94 Million SEK | 4.63% |
| 2016 Q4 | 50.27 Million SEK | 7.09% |
| 2016 Q2 | 44.86 Million SEK | 13.57% |
| 2016 FY | 50.27 Million SEK | 36.2% |
| 2015 Q2 | 38.44 Million SEK | -26.03% |
| 2015 Q4 | 36.91 Million SEK | -9.42% |
| 2015 FY | 36.91 Million SEK | -27.56% |
| 2015 Q1 | 51.97 Million SEK | 2.01% |
| 2015 Q3 | 40.74 Million SEK | 5.98% |
| 2014 Q3 | 44.03 Million SEK | 20.07% |
| 2014 Q4 | 50.95 Million SEK | 15.72% |
| 2014 Q1 | 47.88 Million SEK | -14.58% |
| 2014 FY | 50.95 Million SEK | -9.11% |
| 2014 Q2 | 36.67 Million SEK | -23.42% |
| 2013 FY | 56.05 Million SEK | 4.5% |
| 2013 Q1 | 53.2 Million SEK | -0.83% |
| 2013 Q3 | 51.31 Million SEK | -7.94% |
| 2013 Q4 | 56.05 Million SEK | 9.24% |
| 2013 Q2 | 55.73 Million SEK | 4.77% |
| 2012 Q4 | 53.64 Million SEK | 2.49% |
| 2012 Q2 | 38.69 Million SEK | -2.81% |
| 2012 Q1 | 39.81 Million SEK | -24.39% |
| 2012 FY | 53.64 Million SEK | 1.87% |
| 2012 Q3 | 52.33 Million SEK | 35.25% |
| 2011 FY | 52.66 Million SEK | 7.3% |
| 2011 Q4 | 52.66 Million SEK | 34.98% |
| 2011 Q3 | 39.01 Million SEK | -19.96% |
| 2011 Q1 | 38.57 Million SEK | -21.4% |
| 2011 Q2 | 48.74 Million SEK | 26.37% |
| 2010 Q1 | 26.91 Million SEK | -30.19% |
| 2010 Q2 | 34.67 Million SEK | 28.82% |
| 2010 FY | 49.07 Million SEK | 27.3% |
| 2010 Q3 | 44.79 Million SEK | 29.2% |
| 2010 Q4 | 49.07 Million SEK | 9.57% |
| 2009 Q3 | 34.55 Million SEK | 12.0% |
| 2009 FY | 38.55 Million SEK | -23.64% |
| 2009 Q2 | 30.85 Million SEK | 0.0% |
| 2009 Q4 | 38.55 Million SEK | 11.56% |
| 2008 FY | 50.48 Million SEK | 109.95% |
| 2008 Q4 | 50.48 Million SEK | 0.0% |
| 2007 FY | 24.04 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -1830.56% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 92.06% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 92.06% |
| Arcoma AB | 33.3 Million SEK | -537.511% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 35.601% |
| BICO Group AB (publ) | 3.26 Billion SEK | 93.496% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 24.143% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -1395.548% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -2991.06% |
| C-Rad AB (publ) | 122.4 Million SEK | -73.467% |
| Duearity AB (publ) | 17.53 Million SEK | -1111.198% |
| Dignitana AB (publ) | 37.56 Million SEK | -465.185% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -972.338% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.14% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -930.679% |
| Iconovo AB (publ) | 14.55 Million SEK | -1358.874% |
| Integrum AB (publ) | 22.07 Million SEK | -861.919% |
| Luxbright AB (publ) | 7 Million SEK | -2933.134% |
| Mentice AB (publ) | 163.55 Million SEK | -29.818% |
| OssDsign AB (publ) | 105.25 Million SEK | -101.719% |
| Paxman AB (publ) | 44.5 Million SEK | -377.034% |
| Promimic AB (publ) | 16.15 Million SEK | -1214.205% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -241.526% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -897.852% |
| ScandiDos AB (publ) | 37.18 Million SEK | -470.976% |
| Sectra AB (publ) | 1.64 Billion SEK | 87.064% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -381.873% |
| Senzime AB (publ) | 58.06 Million SEK | -265.664% |
| SpectraCure AB (publ) | 14.97 Million SEK | -1317.85% |
| Stille AB | 172.64 Million SEK | -22.986% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 94.211% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 15.263% |